2nd generation TKIs to first line therapy

Similar documents
HOW I TREAT CML. 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek,

2 nd Generation TKI Frontline Therapy in CML

New drugs in first-line therapy

ELN Recommendations on treatment choice and response. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy

Outlook CML 2016: What is being done on the way to cure

Role of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML. GIUSEPPE SAGLIO, MD University of Torino, Italy

CML: Living with a Chronic Disease

Contemporary and Future Approaches in CML. Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D.

IRIS 8-Year Update. Management of TKI Resistance Will KD mutations matter? Sustained CCyR on study. 37% Unacceptable Outcome 17% 53% 15%

Contemporary and Future Approaches in Management of CML. Disclosures

What is New in CML in Hagop Kantarjian, M.D. February 2011

Guidelines and real World: Management of CML in chronic and advanced phases. Carolina Pavlovsky. FUNDALEU May 2017 Frankfurt

CML: Yesterday, Today and Tomorrow. Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center

How I treat high risck CML

Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase

Chronic Myeloid Leukaemia

What is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR

CML and Future Perspective. Hani Al-Hashmi, MD

The BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine

A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.

BMS Satellite Symposium

State of the Art Therapy and Monitoring of CML Hagop Kantarjian, M.D. Grand Rounds Hackensack, New Jersey. September 22, 2010

SESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy

Juan Luis Steegmann Hospital de la Princesa. Madrid. JL Steegmann

Dose reduction. What do we know and how we do it in clinical practice. Andreas Hochhaus

CML David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML Current treatment options for CML

Molecular monitoring of CML patients

Chronic myeloid leukemia (CML) Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University

State of the Art Therapy and Monitoring of CML Hagop Kantarjian, M.D. Grand Rounds UT Southwestern. October 28, 2010

Starting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019

What is New in CML Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia MD Anderson Cancer Center Houston, Texas

Management of CML in blast crisis. Lymphoma Tumor Board November 27, 2015

Post ASH Actualités LMC

NEW DRUGS IN HEMATOLOGY Bologna, 9-11 May 2016 CHRONIC MYELOID LEUKEMIA STATUS OF THE ART OF TREATMENT.

The concept of TFR (Treatment Free Remission) in CML

Long-term side effects, comorbidities & their impact on choice of treatment CML management and quality of life. Andreas Hochhaus

Accepted Manuscript. Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors. Pradnya Chopade, Luke P.

C Longer follow up on IRIS data

La terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane

Allogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra

Imatinib & Ponatinib. Two ends of the spectrum in 2016s reality

NEW DRUGS IN HEMATOLOGY

New drugs and trials. Andreas Hochhaus

pan-canadian Oncology Drug Review Final Clinical Guidance Report Bosutinib (Bosulif) for Chronic Myelogenous Leukemia April 21, 2015

Does Generic Imatinib Change the Treatment Approach in CML?

EUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA

Dati sulla sospensione della terapia

Quality of Life in Patients with Chronic Myeloid Leukemia

RESEARCH ARTICLE. Introduction. Methods Wiley Periodicals, Inc.

What is New in Leukemia & MPN in 2011?

Venice Meeting Highlights: Key lessons. Conclusions Michele Baccarani Rüdiger Hehlmann

I nuovi guariti? La malattia minima residua nella leucemia mieloide cronica. Fabrizio Pane

Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute

Oxford Style Debate on STOPPING Treatment.

CML EHA: what s new? Novità dall EHA >> [ Leucemia mieloide cronica ] Relatore: G. MARTINELLI. Borgo S. Luigi Monteriggioni (Siena) ottobre 2008

LEUKEMIA ANCO s ASH Highlights TOPICS

1794 Updating Long-Term Outcome of Intermittent Imatinib. (INTERIM) Treatment in Elderly Patients with Ph+-CML

Decision Making in CML 2010

CML Update 2016 Arthur 2016

10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD

CML: definition. CML epidemiology. CML diagnosis. CML: peripheralbloodsmear. Cytogenetic abnormality of CML

Oncology Highlights: Leukemia & Myelodysplastic Syndromes

Should nilotinib replace imatinib as first line treatment of chronic myeloid leukemia in chronic phase (CML-CP)?

Study Design and Endpoints

Stopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN!

Current Monitoring for CML: Goals and. Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center

Stopping treatment how much we understand about mechanisms to stop successfully today, and where are the limits? Andreas Hochhaus

Practical Guidance for the Management of CML in 2016

History of CML Treatment

Welcome and Introductions

When to change therapy? Andreas Hochhaus Universitätsklinikum Jena, Germany

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients

Taiwan Guidelines for the Management of Chronic Myeloid Leukemia

CHRONIC MYELOID LEUKEMIA (CML) Managing the Long and the Short of It

Horizon Scanning in Oncology

CML UPDATE 2018 DAVID S. SNYDER, M.D. MARCH

ARIAD Pharmaceuticals, Inc.

The current standard of care in CML. Gianantonio Rosti, MD University of Bologna Bologna, Italy

What Can We Expect from Imatinib? CML Case Presentation. Presenter Disclosure Information. CML Case Presentation (cont)? Session 2: 8:15 AM - 9:00 AM

Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body

Diagnosis and Management of Chronic Myeloid Leukaemia

Is there a best TKI for chronic phase CML?

DAVID S. SNYDER, M.D.

HSCT for Myeloproliferative Disorders. Jane Apperley

Impact of Age on Efficacy and Toxicity of Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Implementation of Management Guidelines

Treatment free remission in CML: from the concept to practice. François-Xavier Mahon. Cancer Center Bordeaux Université Bordeaux, France

Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: What s Stopping us from Stopping?

Chronic Myeloid Leukemia - ASH

The speaker has no financial relationships with a commercial interest to disclose and no conflicts of interest to resolve.

Blast Phase Chronic Myelogenous Leukemia

Supplementary Online Content

Molecular pathogenesis of CML: Recent insights

pan-canadian Oncology Drug Review Final Clinical Guidance Report Ponatinib (Iclusig) for Chronic Myeloid Leukemia / Acute Lymphoblastic Leukemia

A COMPARATIVE EFFECTIVENESS ANALYSIS OF PATIENTS NEWLY INITIATING TYROSINE KINASE INHIBITOR THERAPY FOR CHRONIC MYELOID LEUKEMIA.

Measuring Response to BCR-ABL Inhibitors in Chronic Myeloid Leukemia

Executive summary Overview

Approval based on the successful BFORE Phase 3 study conducted by Avillion under a collaborative development agreement with Pfizer

Nilotinib AEs (adverse events) in CML population:

Generics from a Hematologist Perspective

Transcription:

New Horizons 2011 Newly diagnosed CML moving 2nd generation TKIs to first line therapy Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA CML Working Party

Imatinib: 12-months CCyR and MMR rates Across CML Frontline Trial Baccarani et al, Blood 2010: abs n. 668)

559 Pts, Imatinib FL, 2003-2007 Estimated OS, PFS, FFS, EFS Events Failures Progressions Deaths N 169 132 67 54 GIMEMA, 2011 (data on file, unpublished) GIMEMA CML WP

Higher MMR Leads to Lower Progression to Advanced Disease for Nilotinib Nilotinib 300 mg BID Nilotinib 400 mg BID Imatinib 400 mg QD P<0.00010001 60 P<0.0001 20 P=0.0095 % MMR 50 44 43 40 MMR = AP/BC 30 22 20 10 2 Num mber of patients with event 15 10 5 P=0.0037 1 11 0 MMR - Month 12 0 Progression to AP/BC No patient who progressed to AP/BC achieved MMR on study

DASISION: First-Line Dasatinib vs Imatinib in CML-CP Confirmed CCyR Rate By Month Of Treatment onfirme ed CCy yr, % C 100 80 60 40 20 0 P=0.0086 P=0.0366 77 78 67 70 Mo 12 Mo 18 Dasatinib 100 mg QD Imatinib 400 mg QD Confirmed CCyR (CCyR detected in 2 consecutive assessments) by 12 mos = primary endpoint Shah et al, ASH 2010

DASISION: First-Line Dasatinib vs Imatinib in CML-CP Transformation To Advanced Phase CML 100 6 Progresse ed to AP/ /BP, % 100 4 2 0 Dasatinib 100 mg QD Imatinib 400 mg QD 2,3 5 patients who achieved a CCyR progressed to AP/BP CML (2 dasatinib, 3 imatinib) 3,5 n/n 6/259 9/260 No patient who achieved a MMR progressed to AP/BP CML to date P ti t f ll d f t f ti f t 60 d ft th l t d f Patients were followed for transformation for up to 60 days after the last dose of study drug. Clonal evolution without additional criteria for AP CML was not counted as transformation Shah et al, ASH 2010

Overall Survival* ENESTnd: Nilotinib vs Imatinib in CML-CP Nilotinib 300 mg BID n = 282 Nilotinib 400 mg BID n = 281 Imatinib 400 mg gqd n = 283 Total number of deaths 9 6 11 Estimated 24-month rate of OS 97.4% 97.8% 96.3% P-value (OS) 0.6485 0.2125 CML-unrelated 4 3 1 CML-related 5 3 10 Estimated 24-month rate of OS considering only CML deaths 98.9% 98.9% 96.7% P-value (CML deaths) 0.1930 0.04850485 *ITT population Including deaths after discontinuation of treatment 7 Data cut-off: 20Aug2010

DASISION: First-Line Dasatinib vs Imatinib in CML-CP Patient Disposition And Treatment Discontinuations Number (%) of treated patients Dasatinib 100 mg QD N = 258 Imatinib 400 mg QD N = 258 Still on treatment 210 (81) 206 (80) Discontinued 48 (19) 52 (20) Progression* 9 (3) 13 (5) Treatment Failure 6 (2) 11 (4) Adverse event (AE) 16 (6) 11 (4) Non-hematologic 9 (3) 8 (3) Hematologic 7 (3) 3 (1) Unrelated AE 5 (2) 1 (<1) Death 4(2) 1(<1) Other 8 (3) 15(6) *Increasing WBC count; loss of CHR; loss of MCyR including 30% rise in Ph+ metaphases and additional chromosomal abnormalities; or progression to AP/BP PFS rates at 18 mos were 94.9% for dasatinib and 93.7% for imatinib Overall, there have been 11 deaths in the dasatinib arm, including 1 newly reported death due to bladder cancer; and 6 deaths in the imatinib arm. At this early time point, OS rates at 18 mos were 96.0% for dasatinib and 97.9% for imatinib Includes consent withdrawal, loss to follow-up, pregnancy, patient request and poor/non compliance

ENESTnd: Nilotinib vs Imatinib in CML-CP Study Drug-Related Adverse Events and Grade 3/4 Myelosuppression Fluid retention Diarrhea Headache Muscle Spasm Any grade Grade 3/4 Nausea Pruritis Rash Vomiting Anemia Neutropenia Thrombocytopenia -0.5-0.4-0.3-0.2-0.1 Favors imatinib 9 0 0.1 0.2 0.3 0.4 0.5 Rate difference (imatinib - nilotinib) with 95% CI Favors nilotinib (300 mg BID) Data cut-off: 20Aug2010

DASISION: First-Line Dasatinib vs Imatinib in CML-CP Forest Plots Comparing Differences In AE Rates Fluid retention 60 Superficial edema 25 Pleural effusion 31 Myalgia 56 Nausea 23 Any grade Vomiting 12 Diarrhea 47 Fatigue 21 Headache 32 Rash 29 Neutropenia 57 Grade 3/4 Thrombocytopenia 49 Anemia 29 No. of patients Dasatinib -0.4-0.2 0.0 0.2 0.4 Rate Difference (dasatinib-imatinib) with Exact 95% CI Imatinib 111 92 0 99 55 27 50 28 27 44 52 27 18 Favors dasatinib Favors imatinib

The Optimal Frontline Strategy for CML CONDITIONS Imatinib 1. Same long-term leukemia free CML Early CP survival 2 nd Generation TKI 2 nd Generation TKI 2. Same rate of progression to AP/BP 3. Same QOL EFS EFS

New Horizons 2011 Moving ALL NEWLY DIAGNOSED PATIENTS TO 2nd gen. TKIs AS first line therapy Costs Brief-term safety Long-term safety..

European LeukemiaNet recommendations Optimal Response Suboptimal Response Failure Warnings Baseline NA NA NA High risk 3 Months CHR and at least minor CyR (Ph+ 65%) 6 Months At least PCyR (Ph+ 35%) (Ph+ > 35%) No CyR (Ph+ > 95%) Less than CHR NA Less than PCyR 12 Months CCyR PCyR (Ph+ 1-35%) No CyR Less than PCyR 18 Months MMR b Less than MMR b Less than CCyR NA CCA/Ph+ a NA Less than MMR b Baccarani M, et al. J Clin Oncol. 2009;27:6041-6051.

Treating CML after Resistance to Imatinib With second generation TKIs The 80% of 40% Rule Nilotinib & Dasatinib > CCyR rate 40% 80% CCyR are stable at 24 months 80% of 40% Rule: 30% rescued properly Kantarjian HM, et al. Haematologica. 2009; and and Shah et al. Hematologica 2010

European LeukemiaNet recommendations Optimal Response Suboptimal Response Failure Warnings Baseline NA NA NA High risk 3 Months CHR and at least minor CyR (Ph+ 65%) 6 Months At least PCyR No CyR (Ph+ > 95%) Less than PCyR Less than CHR No CyR (Ph+ 35%) (Ph+ > 35%) (Ph+ > 95%) 12 Months CCyR PCyR (Ph+ 1-35%) Less than PCyR (Ph+ >35%) 18 Months MMR b Less than MMR b Less than CCyR CCA/Ph+ a NA NA Less than MMR b NA Baccarani M, et al. J Clin Oncol. 2009;27:6041-6051.

Higher MMR Leads to Lower Progression to Advanced Disease for Nilotinib Nilotinib 300 mg BID Nilotinib 400 mg BID Imatinib 400 mg QD 60 P<0.00010001 RELEVANT PROBLEM P<0.0001 20 P=0.0095 % MMR 50 40 44 43 A DECISION POINT TO IMPLEMENT 15 P=0.0037 2 nd GENERATION TKIs EARLY ON, ABOLISHING 11 THE MMR = AP/BC RISK OF PROGRESSION 10 IS NOT (YET) 22 AVAILABLE 30 20 10 2 0 0 MMR - Month 12 Progression to AP/BC Num mber of patients with event 5 1 No patient who progressed to AP/BC achieved MMR on study

% respo onding IRIS: Estimated CCyR to First-line Imatinib by Sokal Group 100 90 80 70 60 95% CI 91% (87-96) 84% (76-92) 69% (58-81) 81) 50 p< 0.001 40 30 n=201 20 10 0 Low risk Intermediate risk High risk n=111 n=71 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 Months since randomization Druker et al. NEJM 2006; 355: 2408-17

% MM MR 80 70 60 50 40 30 20 10 0 ENESTnd: Nilotinib vs Imatinib in CML-CP MMR Rates by 24 Months According to Sokal Risk* P =.003 P =.002 P<.0001 73 74 74 53 67 P =.0008 44 65 P <.0001 56 P =.002 n = 103 103 104 101 100 101 78 78 78 Low Intermediate High 32 Nilotinib 300 mg BID Nilotinib 400 mg BID Imatinib 400 mg QD *ITT population; P values are provided for descriptive purposes only and are not adjusted for multiple comparisons 19 Data cut-off: 20Aug2010

New Horizons 2011 Newly diagnosed CML moving 2nd generation TKIs to first line therapy Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA CML Working Party